for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

アボット・ラボラトリーズ

ABT.N

現在値

123.31USD

変化

3.97(+3.33%)

出来高

1,930,086

本日のレンジ

122.21

 - 

124.80

52週レンジ

103.13

 - 

129.67

∙ 約20分前の相場を表示しています。

適時開示

Abbott Laboratories Receives FDA Approval For Minimally Invasive Portico With FlexNav TAVR System

Sept 20 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT RECEIVES FDA APPROVAL FOR MINIMALLY INVASIVE PORTICO™ WITH FLEXNAV™ TAVR SYSTEM TO TREAT PATIENTS WITH AORTIC VALVE DISEASE.

Abbott Laboratories Says Guide-Hf Study Data Show Abbott's Cardiomems Device Can Improve Care For More Patients With Heart Failure

Aug 27 (Reuters) - Abbott Laboratories <ABT.N>::GUIDE-HF STUDY DATA SHOW ABBOTT'S CARDIOMEMS™ DEVICE CAN IMPROVE CARE FOR MORE PATIENTS WITH HEART FAILURE.ABBOTT LABORATORIES - DATA FROM GUIDE-HF TRIAL SUGGESTS CARDIOMEMS CAN IMPROVE CARE FOR MORE TYPES OF PATIENTS BATTLING HEART FAILURE.ABBOTT- DATA FROM GUIDE-HF TRIAL SUGGESTS CARDIOMEMS CAN REDUCE HOSPITALIZATIONS FOR PATIENTS BATTLING HEART FAILURE.ABBOTT LABORATORIES - RESULTS OF GUIDE-HF WERE PRESENTED AT ESC CONGRESS 2021 AND SIMULTANEOUSLY PUBLISHED IN LANCET.ABBOTT LABORATORIES - FILED A PREMARKET APPROVAL (PMA) SUPPLEMENT WITH U.S. FDA FOR CONSIDERATION OF AN EXPANDED INDICATION FOR CARDIOMEMS DEVICE.

Abbott Q2 Adjusted Earnings Per Share $1.17

July 22 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT REPORTS SECOND-QUARTER 2021 RESULTS.SEES FY ADJUSTED EARNINGS PER SHARE $4.30 TO $4.50 FROM CONTINUING OPERATIONS.SEES FY GAAP EARNINGS PER SHARE $2.75 TO $2.95 FROM CONTINUING OPERATIONS.Q2 ADJUSTED EARNINGS PER SHARE $1.17.Q2 GAAP EARNINGS PER SHARE $0.66.Q2 SALES $10.2 BILLION VERSUS REFINITIV IBES ESTIMATE OF $9.69 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $1.02 -- REFINITIV IBES DATA.FY2021 EARNINGS PER SHARE VIEW $4.36 -- REFINITIV IBES DATA.QTRLY TOTAL DIAGNOSTICS SALES $3.25 BILLION.WORLDWIDE DIAGNOSTICS SALES UP 62.8% ON A REPORTED BASIS IN Q2.QTRLY TOTAL MEDICAL DEVICES SALES $3.67 BILLION.WORLDWIDE MEDICAL DEVICES SALES UP 51.3% ON A REPORTED BASIS IN Q2.

Abbott Laboratories Reports Q2 COVID-19 test sales of $1.3 bln

July 22 (Reuters) - Abbott Laboratories::QUARTERLY ADJUSTED EPS $1.17.QUARTERLY NET SALES $10.2 BILLION.QUARTERLY COVID-19 TEST SALES OF $1.3 BILLION.QUARTERLY DIAGNOSTICS REVENUE UP MORE THAN 57%.Further company coverage: ABT.N. ((Reuters.Briefs@thomsonreuters.com;)).

Abbott's Xience Stent Receives FDA Approval For Shortest Blood Thinner Course For High Bleeding Risk Patients

June 30 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT'S XIENCE STENT RECEIVES FDA APPROVAL FOR SHORTEST BLOOD THINNER COURSE FOR HIGH BLEEDING RISK PATIENTS.

Abbott Laboratories Approved A Restructuring Plan

June 3 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT LABORATORIES - APPROVED A RESTRUCTURING PLAN.ABBOTT LABORATORIES - ESTIMATES PRE-TAX COSTS TO BE INCURRED TO IMPLEMENT PLAN TO BE APPROXIMATELY $550 MILLION TO $700 MILLION.ABBOTT LABORATORIES - COSTS ARE EXPECTED TO BE INCURRED DURING REMAINDER OF 2021 WITH MAJORITY OF COSTS EXPECTED TO BE RECORDED IN Q2 OF 2021.ABBOTT LABORATORIES - COSTS WILL INCLUDE FIXED ASSET WRITE-DOWNS OF $100 MILLION TO $135 MILLION, INVENTORY-RELATED CHARGES OF $220 MILLION TO $265 MILLION.ABBOTT LABORATORIES - NON-CASH CHARGES INCLUDED IN TOTAL ARE ESTIMATED TO BE $320 MILLION TO $400 MILLION.

Abbott Sees Q2 GAAP Earnings Per Share At Least $0.39 From Continuing Operations

June 1 (Reuters) - Abbott Laboratories <ABT.N>::SEES FY ADJUSTED EARNINGS PER SHARE $4.30 TO $4.50 FROM CONTINUING OPERATIONS.SEES Q2 ADJUSTED EARNINGS PER SHARE AT LEAST $1.00 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY GAAP EARNINGS PER SHARE $2.75 TO $2.95 FROM CONTINUING OPERATIONS.SEES Q2 GAAP EARNINGS PER SHARE AT LEAST $0.39 FROM CONTINUING OPERATIONS.UPDATED OUTLOOK REFLECTS LOWER RECENT AND PROJECTED DEMAND FOR COVID-19 TESTS.FY2021 EARNINGS PER SHARE VIEW $5.04 -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $1.23 -- REFINITIV IBES DATA.

Generic Pharmasec Enters Agreement With Abbott Point Of Care

May 31 (Reuters) - Generic Pharmasec Ltd <GENP.BO>::GENERIC PHARMASEC LTD - ENTERS AGREEMENT WITH ABBOTT POINT OF CARE.

Abbott Reports ​$2.2 Bln Q1 Sales From COVID-19 Tests

April 20 (Reuters) - Abbott Laboratories Inc:QUARTERLY ADJUSTED EARNINGS PER SHARE $1.32.QUARTERLY DIAGNOSTICS BUSINESS GREW OVERALL NEARLY 115%.QUARTERLY WORLDWIDE SALES GREW NEARLY 33%.SAYS RECORDED ​$2.2 BILLION REVENUE FROM COVID-19 TESTS IN Q1.MEDICAL DEVICE SEGMENT GREW NEARLY 9% IN Q1 LED BY DIABETES CARE.

Abbott Reports Q1 Adj. Earnings Of $1.32/Share

April 20 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT REPORTS FIRST-QUARTER 2021 RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $1.32.Q1 GAAP EARNINGS PER SHARE $1.00.Q1 SALES ROSE 35.3 PERCENT TO $10.5 BILLION.PROJECTED FULL-YEAR EPS REMAINS UNCHANGED.Q1 EARNINGS PER SHARE VIEW $1.27, REVENUE VIEW $10.69 BILLION -- REFINITIV IBES DATA.QUARTERLY TOTAL DIAGNOSTICS SALES $4.01 BILLION VERSUS $1.83 BILLION REPORTED LAST YEAR.SEES FY ADJUSTED EARNINGS PER SHARE AT LEAST $5.00 FROM CONTINUING OPERATIONS.FY2021 EARNINGS PER SHARE VIEW $5.04 -- REFINITIV IBES DATA.QTRLY TOTAL MEDICAL DEVICES SALES $3.32 BILLION VERSUS $2.94 BILLION REPORTED LAST YEAR.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up